Research Topics
Genomes and GenesSpecies | Krista L LanctotSummaryAffiliation: Sunnybrook Health Sciences Centre Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populationsB Paes
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
Eur J Pediatr 171:833-41. 2012..In infants receiving palivizumab, those with underlying medical disorders, though not currently approved for prophylaxis, are at higher risk for RI events compared with preterm infants. However, risk of RSV hospitalizations is similar...
Apathy associated with Alzheimer disease: use of dextroamphetamine challengeKrista L Lanctot
Department of Psychiatry, University of Toronto, Toronto, Canada
Am J Geriatr Psychiatry 16:551-7. 2008..To assess the role of the dopaminergic brain reward system (BRS) in apathy associated with Alzheimer disease (AD)...
Behavioral correlates of GABAergic disruption in Alzheimer's diseaseKrista L Lanctot
Neuropharmacology Research Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Int Psychogeriatr 19:151-8. 2007..Our objective was to assess the relationship between plasma GABA (pGABA) levels and specific BPSD in patients with severe AD...- A SPECT study of apathy in Alzheimer's diseaseKrista L Lanctot
Department of Psychiatry, University of Toronto, Toronto, Ont, Canada
Dement Geriatr Cogn Disord 24:65-72. 2007..To assess the association between regional cerebral blood flow (rCBF) and apathy in Alzheimer's Disease (AD)... - A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer diseaseKrista L Lanctot
Neuropharmacology Research Program and Geriatric Psychiatry, Toronto, Ontario, Canada
Am J Geriatr Psychiatry 15:888-98. 2007..Postmortem studies suggest decreased 5-HT(1A) receptors in patients with Alzheimer disease (AD), but this has not been confirmed in vivo. Our primary objective was to assess the extent of 5-HT(1A) receptor losses in mild to moderate AD... - Therapy for Alzheimer's Disease: How Effective are Current Treatments?Krista L Lanctot
Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Ther Adv Neurol Disord 2:163-80. 2009..This has spurred the development of new disease-modifying therapies that aim to have a greater impact on this debilitating illness... - Serotonin-1A receptors in frontotemporal dementia compared with controlsKrista L Lanctot
Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Psychiatry Res 156:247-50. 2007..These pilot data suggest that profound 5-HT(1A) BP losses may be present and contribute to symptomatology and treatment response in FTLD... - The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis Krista L Lanctot
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Curr Med Res Opin 24:3223-37. 2008..The cost-effectiveness of this therapy in Canada is unknown... - Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injuryKrista L Lanctot
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Brain Inj 24:959-69. 2010..To determine which serotonergic system-related single nucleotide polymorphisms (SNPs) predicted variation in treatment response to citalopram in depression following a traumatic brain injury (TBI)... - Commentary: Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levelsKrista L Lanctot
Neuropsychopharmacology Research Program, Sunnybrook Health Sciences Centre, Canada
Exp Neurol 212:251-4. 2008 - The serotonin transporter polymorphisms and major depression following traumatic brain injuryFlorance Chan
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Brain Inj 22:471-9. 2008..The purpose of this study was to examine the role of the serotonin transporter gene polymorphisms on the risk of major depression following traumatic brain injury (TBI)... - The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohortPearl Behl
Linda C Campbell Cognitive Neurology Research Unit, University of Toronto, Canada
Int Psychogeriatr 20:1141-59. 2008..This study seeks to assess change in activities of daily living (ADLs) over two years in AD patients treated with CHEIs matched to untreated patients in the same longitudinal cohort study... - Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challengeNathan Herrmann
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
J Clin Psychopharmacol 28:296-301. 2008..Psychostimulants may be effective in treating features of apathy in AD, and dopaminergic changes may predict response... - The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairmentAllison B Gold
Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
J Neuroinflammation 8:17. 2011.... - A functional neuroimaging study of appetite loss in Alzheimer's diseaseZahinoor Ismail
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
J Neurol Sci 271:97-103. 2008..Alzheimer's Disease (AD) is frequently associated with changes in appetite. This study investigated the relationship between regional cerebral perfusion and appetite loss in AD... - A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injuryMark J Rapoport
Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
J Clin Psychiatry 71:1125-30. 2010..This study examines whether continuation therapy with citalopram can prevent a relapse following remission of major depression due to traumatic brain injury... - Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infantsAnna Banerji
Department of Pediatrics and Dalla Lana School of Public Health, St Michael s Hospital, University of Toronto, Toronto, Canada
Pediatr Infect Dis J 28:702-6. 2009.... - Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementiaNathan Herrmann
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Am J Geriatr Psychiatry 20:789-97. 2012.... - Are vascular risk factors associated with post-stroke depressive symptoms?Gayla Tennen
Department of Clinical Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
J Geriatr Psychiatry Neurol 24:215-21. 2011..The objective of the current study was to determine whether VRFs are associated with the risk of PSD in an acute stroke population... - The relationship between inflammatory markers and post stroke cognitive impairmentLana S Rothenburg
Neuropsychopharmacology Research Group, Toronto, Ontario, Canada
J Geriatr Psychiatry Neurol 23:199-205. 2010..Enzyme-linked immunosorbent assay (ELISA) was used to measure serum concentrations of CRP, interleukin 6 (IL-6), and interferon gamma (IFN-gamma)... - Validity and responsiveness to change of clinically derived MDS scales in Alzheimer disease outcomes researchKelly A Smart
Neuropsychopharmacology Research Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
J Geriatr Psychiatry Neurol 24:67-72. 2011..As these findings are preliminary, further research is needed to determine the utility of MDS scales in outcomes research... - Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patientsNathan Herrmann
Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
J Psychopharmacol 18:215-20. 2004..Individual patient characteristics, including underlying neurotransmitter changes, may be useful for predicting response to therapy... - Major depressive disorder predicts completion, adherence, and outcomes in cardiac rehabilitation: a prospective cohort study of 195 patients with coronary artery diseaseWalter Swardfager
Neuropharmacology Research Group, Sunnybrook Health Sciences Centre, Canada
J Clin Psychiatry 72:1181-8. 2011..To compare completion, adherence, and cardiac rehabilitation (CR) outcomes between participants with and without major depressive disorder (MDD) undertaking CR... - Verbal memory performance and completion of cardiac rehabilitation in patients with coronary artery diseaseWalter Swardfager
Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Psychosom Med 73:580-7. 2011..To assess cognitive performance as a predictor of noncompletion of cardiac rehabilitation (CR) using a standardized verbal memory test... - Cardiopulmonary fitness is associated with cognitive performance in patients with coronary artery diseaseWalter Swardfager
Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
J Am Geriatr Soc 58:1519-25. 2010..To investigate the association between cardiopulmonary fitness and cognitive performance in subjects with coronary artery disease (CAD)... - Adverse drug events in cognitively impaired elderly patientsHooman Ganjavi
Neuropharmacology Research, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Dement Geriatr Cogn Disord 23:395-400. 2007..Adverse drug events (ADEs) are a frequent problem encountered in the elderly. The aim of this study was to elucidate the factors that influence ADEs in an elderly population with cognitive impairment... - A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's diseaseNathan Herrmann
Neuropharmacology Research Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Dement Geriatr Cogn Disord 23:116-9. 2007..To assess the efficacy and tolerability of valproate for the treatment of agitation and aggression in moderate-to-severe Alzheimer's disease (AD)... - Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden?Karen Levy
Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Drugs Aging 29:167-79. 2012..Given the importance of caregiver burden and its negative consequences for the caregiver and the patient, future clinical trials should pay more attention to this crucial outcome... - Factor analysis of the Rivermead Post-Concussion Symptoms Questionnaire in mild-to-moderate traumatic brain injury patientsNathan Herrmann
Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada
J Neuropsychiatry Clin Neurosci 21:181-8. 2009..These results suggest that depression post-TBI may influence patient perception of postconcussion symptoms... - The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian ArcticDerrick Y Tam
Medical Outcomes and Research in Economics Group, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
J Med Econ 12:361-70. 2009..Canadian, Inuit, full term infants have the highest rate of respiratory syncytial virus (RSV) infection globally, which results in substantial costs associated hospitalisation... - Central serotonergic activity is related to the aggressive behaviors of Alzheimer's diseaseKrista L Lanctot
Psychopharmacology Research Program and Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
Neuropsychopharmacology 27:646-54. 2002..These results suggest a complex link between aggression in AD and central serotonergic dysfunction having interactions with gender and cognitive impairment... - The relation between disease severity and cost of caring for patients with Alzheimer disease in CanadaNathan Herrmann
Medical Outcomes and Research in Economics MORE Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Can J Psychiatry 55:768-75. 2010..to characterize the cost of caring for an outpatient in Canada with Alzheimer disease (AD) based on disease severity, and to describe how costs change with increases in disease severity... - Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot studyNathan Herrmann
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
CNS Drugs 25:425-33. 2011..Agitation and aggression are common neuropsychiatric symptoms of Alzheimer's disease (AD) with a negative impact on caregivers... - Growth hormone response to clonidine predicts aggression in Alzheimer's diseaseNathan Herrmann
Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre, Room FG05, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
Psychoneuroendocrinology 29:1192-7. 2004..The neurobiology of aggression in Alzheimer's Disease (AD) remains unknown. The objective of this study was to determine if altered central noradrenergic (NE) responsiveness is related to aggression in AD... - Do atypical antipsychotics cause stroke?Nathan Herrmann
Division of Geriatric Psychiatry, University of Toronto, Toronto, Ontario, Canada
CNS Drugs 19:91-103. 2005..At the present time, this association is another factor that clinicians should consider when weighing the risks and benefits of treating behavioural and psychological disturbances in elderly dementia patients... - Higher cortisol predicts less improvement in verbal memory performance after cardiac rehabilitation in patients with coronary artery diseaseMahwesh Saleem
Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5 Department of Pharmacology and Toxicology, University of Toronto, 1 King s College Circle, Toronto, ON, Canada M5S 1A8
Cardiovasc Psychiatry Neurol 2013:340342. 2013..12), maximal oxygen uptake (F(1,50) = 1.88, P = 0.18), and body mass index (F(1,50) = 3.25, P = 0.08). Conclusion. Prolonged hypothalamic pituitary adrenal axis activation may interfere with exercise-related improvements in memory in CAD... - CARESS: the Canadian registry of palivizumabIan Mitchell
Department of Pediatrics, University of Calgary, Alberta Children s Hospital, Calgary, AB, Canada
Pediatr Infect Dis J 30:651-5. 2011..Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children. However, relatively little is known about the current use, compliance, and outcomes associated with this medication... - The role of norepinephrine in the behavioral and psychological symptoms of dementiaNathan Herrmann
Division of Geriatric Psychiatry, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON M4N 3M5, Canada
J Neuropsychiatry Clin Neurosci 16:261-76. 2004..With greater appreciation of the underlying neurobiology of behavioral and psychological symptoms of dementia (BPSD) more effective, rational, targeted pharmacotherapy will hopefully emerge... - Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia expertsNathan Herrmann
Department of Psychiatry and Faculty of Medicine, University of Toronto, and Division of Geriatric Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Int Psychogeriatr 23:539-45. 2011..Because there is little data to help clinicians to decide on when it is safe and appropriate to discontinue ChEIs after long-term use, practices may vary widely... - Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysisYekta Dowlati
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario
Can J Psychiatry 55:91-9. 2010..Our objective was to quantitatively summarize the data on the efficacy and tolerability of antidepressant (AD) treatment for depression in CAD... - Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analysesMark Sinyor
Department of Psychiatry, University of Toronto, Ontario, Canada
J Clin Psychiatry 71:270-9. 2010..To determine if the inclusion of a placebo arm and/or the number of active comparators in antidepressant trials influences the response rates of the active medication and/or placebo... - GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementiaKrista L Lanctot
Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario
Can J Psychiatry 49:439-53. 2004..We review the clinical use of GABAergic agents in treating persons with AD symptoms. While newer generation GABAergic medications are now available, they have yet to be evaluated among patients with AD... - Pharmacologic management of neuropsychiatric symptoms of Alzheimer diseaseNathan Herrmann
Department of Psychiatry, University of Toronto, Ontario
Can J Psychiatry 52:630-46. 2007..To systematically review published clinical trials of the pharmacotherapy of neuropsychiatric symptoms of Alzheimer disease (AD)... - Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patientsPearl Behl
Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, 160 Russell Jarvis Drive, Toronto, Ontario, Canada
Arch Neurol 64:266-72. 2007.... - Exercise intervention and inflammatory markers in coronary artery disease: a meta-analysisWalter Swardfager
Sunnybrook Research Institute, Toronto, Ontario, Canada
Am Heart J 163:666-76.e1-3. 2012..We performed a meta-analysis of changes in inflammatory biomarkers over the course of exercise interventions in patients with CAD... - The role of dopamine in symptoms and treatment of apathy in Alzheimer's diseaseRobert A Mitchell
Neuropsychopharmacology, Sunnybrook Health Sciences Centre, Toronto, Canada
CNS Neurosci Ther 17:411-27. 2011..The DAergic system is closely related to the brain reward system (BRS) and some studies have suggested that dysfunction in the DAergic system may account for symptoms of apathy in the AD population... - Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery diseaseWalter Swardfager
Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Psychoneuroendocrinology 34:1560-6. 2009..non-depressed patients (45.6+/-20.0 micromol/mmol vs. 38.5+/-15.7 micromol/mmol, F=3.778, p=.055) when controlling for age, sex and tACS. Activation of IDO is associated with the severity of depressive symptoms among patients with CAD... - The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approachGrace Wu
Department of Psychiatry, HOPE Research Centre and Division of Clinical Pharmacology, Room FG 05, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
CNS Drugs 17:1045-57. 2003..This study aimed to measure the economic value of cholinesterase inhibitors when used to treat Alzheimer's disease using the willingness-to-pay (WTP) approach and the framework of cost-benefit analysis... - Medial temporal hypoperfusion and aggression in Alzheimer diseaseKrista L Lanctot
Neuropharmacology Research, Department of Psychiatry, Cognitive Neurology Unit, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario, Canada
Arch Neurol 61:1731-7. 2004..It is not understood why some patients with Alzheimer disease (AD) display aggression and others do not... - Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysisKrista L Lanctot
Neuropharmacology Research Program, Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON
CMAJ 169:557-64. 2003..Our objective was to quantitatively summarize data on the efficacy and safety of ChEIs in Alzheimer's disease in a format useful to clinicians... - Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's typeTanya Pinto
Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Ageing Res Rev 10:404-12. 2011..Biochemical and neuroimaging studies of BPSD in Alzheimer's patients support these pharmacological data. This review discusses the literature describing the association between cholinergic deficiency and manifestations of BPSD... - Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trialsMark Sinyor
Department of Psychiatry, University of Toronto, Toronto, Canada
J Clin Psychiatry 73:e277-87. 2012..This study aims to determine the relationship between sponsorship and antidepressant dosing and efficacy in randomized controlled trials for major depressive disorder... - The cost effectiveness of palivizumab: a systematic review of the evidenceKelly A Smart
Medical Outcomes and Research in Economics MORE, Sunnybrook Health Sciences Centre and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
J Med Econ 13:453-63. 2010..The objective was to systematically examine the cost effectiveness of palivizumab in defined infant groups and identify important cost and outcome determinants... - Changing costs and the impact on RSV prophylaxisKelly A Smart
Medical Outcomes and Research in Economics Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
J Med Econ 13:705-8. 2010.... - Current and emerging drug treatment options for Alzheimer's disease: a systematic reviewNathan Herrmann
Neuropsychopharmacology Research Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Drugs 71:2031-65. 2011..This systematic review critically examines the efficacy and safety data for currently approved drugs and emerging treatments in AD, as well as discussing the present and future directions of innovation in this field... - A meta-analysis of cytokines in major depressionYekta Dowlati
Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
Biol Psychiatry 67:446-57. 2010..Our objective was to quantitatively summarize the data on concentrations of specific cytokines in patients diagnosed with a major depressive episode and controls... - Effects of omega-3 fatty acids on cognitive performance: a meta-analysisGraham Mazereeuw
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Neurobiol Aging 33:1482.e17-29. 2012..This meta-analysis examined the neuropsychological benefit of n-3 FAs in randomized double-blind placebo-controlled studies (RCTs) including healthy, CIND, or AD subjects... - Relationship between cardiopulmonary fitness and depressive symptoms in cardiac rehabilitation patients with coronary artery diseaseWalter Swardfager
Department of Pharmacology, University of Toronto, Toronto, Canada
J Rehabil Med 40:213-8. 2008..To identify independent predictors of depressive symptoms in a cohort of patients with coronary artery disease entering cardiac rehabilitation... - The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's diseaseJaclyn Cappell
Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
CNS Drugs 24:909-27. 2010.... - Benzodiazepine use and driving: a meta-analysisMark J Rapoport
Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
J Clin Psychiatry 70:663-73. 2009..The purpose of the present study was to examine the experimental and epidemiologic evidence linking benzodiazepine use to driving impairment... - Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children : a case-control studyAnna Banerji
Department of Pediatrics and Dalla Lana School of Public Health, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
Pediatr Infect Dis J 28:697-701. 2009..To examine risk factors for lower respiratory tract infections (LRTI) hospital admission in the Canadian Arctic... - A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practiceBosco A Paes
Department of Pediatrics, McMaster University, Hamilton, Ontario
Can Respir J 18:e10-9. 2011..Prevention strategies and treatment are discussed based on the existing scientific evidence, and future challenges in the management of RSV infection are addressed... - Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's diseaseKrista L Lanctot
Neuropsychopharmacology Research Program and HOPE Research Centre, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ont
J Psychiatry Neurosci 28:13-26. 2003..Studying correlates of response may help to elucidate the mechanism of action of acetylcholinesterase inhibitors... - Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's diseaseKrista L Lanctot
Psychopharmacology Research Program and Geriatric Psychiatry, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, 207s Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
Int J Geriatr Psychiatry 17:531-41. 2002..Indications for serotonergic medications in the treatment of behavioral disorders associated with Alzheimer's disease (AD) remain to be established... - Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?Nathan Herrmann
Department of Psychiatry, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Drug Saf 29:833-43. 2006.... - Atypical antipsychotics and risk of cerebrovascular accidentsNathan Herrmann
Institute for Clinical and Evaluative Sciences, University of Toronto, Toronto, Ontario, Canada
Am J Psychiatry 161:1113-5. 2004..This study examined the association between atypical antipsychotic use and stroke in the elderly... - The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's diseaseSarah Thompson
Sunnybrook and Women's College Health Sciences Centre, Department of Psychiatry, Rm FG-05, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
Expert Opin Drug Saf 3:425-40. 2004..Further study is needed to examine other indications for ChEIs, as well as their combination with newer treatments, such as memantine... - Pediatric cancer rates after universal folic acid flour fortification in OntarioSandy G Grupp
Institute of Medical Science, University of Toronto, Hospital for Sick Children, Toronto, Canada
J Clin Pharmacol 51:60-5. 2011..This corroborates a recent case-control study from Germany. These data may also provide some reassurance that universal flour fortification does not heighten the risk of pediatric cancer... - Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinicJulie M Dergal
Kunin Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada
Drugs Aging 19:879-86. 2002.... - The contribution of neuropsychiatric symptoms to the cost of dementia careNathan Herrmann
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Int J Geriatr Psychiatry 21:972-6. 2006..CONCLUSION: BPSD contribute significantly to the overall costs of dementia care. Interventions targeted at BPSD may help to reduce the staggering societal costs of this illness... - Lithium and its neuroprotective and neurotrophic effects: potential treatment for post-ischemic stroke sequelaeA B Gold
Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue Rm FG 05, Toronto, ON M4N 3M5, Canada
Curr Drug Targets 12:243-55. 2011.... - Perceptions of natural health products among patients attending a memory clinicPapita Sharma
Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
Am J Alzheimers Dis Other Demen 21:156-63. 2006..826, P = .005). Careful questioning during visits with health care providers and better counseling may be necessary to reduce the potential for adverse events and NHP-drug interactions... - Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefitsJennifer Glass
University of Toronto, Department of Pharmaceutical Sciences, Toronto, ON, Canada M5S 2S2
BMJ 331:1169. 2005..In people over 60, the benefits of these drugs may not justify the increased risk, particularly if the patient has additional risk factors for cognitive or psychomotor adverse events... - Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysisMichiel E H Hemels
Department of Pharmacology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Ann Pharmacother 39:803-9. 2005..45 (1.19 to 1.77; n = 3567). No differences were found among antidepressant classes. CONCLUSIONS: Maternal exposure to antidepressants may be associated with increased risk for SA; however, depression itself cannot be ruled out...